Achieve Life Sciences, Inc. (ACHV) Stock Price

ACHVStock

$8.17+171.92%52W

Market Cap$840.71M

P/E—

PEG Ratio17.68

Div yield—

Beta2.36

ACHV Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)78.25%

Price vs S&P 500 (4W)25.43%

PEG Ratio17.68

VGM Score39.93

Book Value / Share (Quarterly)$0.20

P/TBV (Annual)12.74x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-44.67%

Cash Flow / Share (Quarterly)$-0.85

Price vs S&P 500 (YTD)47.80%

Net Profit Margin (TTM)-94.67%

EPS (TTM)$-1.11

10-Day Avg Trading Volume1.72M

EPS Excl Extra (TTM)$-1.11

Revenue Growth (5Y)-1.65%

EPS (Annual)$-1.25

ROI (Annual)-150.10%

Gross Margin (Annual)-98.76%

Net Profit Margin (5Y Avg)-159.73%

Cash / Share (Quarterly)$0.55

ROA (Last FY)-130.77%

Revenue Growth TTM (YoY)-89.25%

EBITD / Share (TTM)$-1.09

ROE (5Y Avg)-222.50%

Operating Margin (TTM)-106.51%

Cash Flow / Share (Annual)$-0.93

P/B Ratio67.94x

P/B Ratio (Quarterly)14.66x

Net Income / Employee (Annual)$-1,951,700

EV / Revenue (TTM)39.97x

Net Interest Coverage (TTM)-88.50x

ROA (TTM)-111.88%

EPS Incl Extra (Annual)$-1.25

Current Ratio (Annual)4.39x

Quick Ratio (Quarterly)2.47x

3-Month Avg Trading Volume1.83M

52-Week Price Return171.92%

Revenue / Employee (TTM)$75,700

Tangible BV / Share (Quarterly)$0.19

P/S Ratio (Annual)143.37x

Asset Turnover (Annual)0.18x

52-Week High$8.61

Operating Margin (5Y Avg)-175.65%

EPS Excl Extra (Annual)$-1.25

CapEx CAGR (5Y)-31.57%

Tangible BV CAGR (5Y)5.41%

26-Week Price Return89.50%

Quick Ratio (Annual)4.01x

13-Week Price Return72.61%

Total Debt / Equity (Annual)0.69x

Current Ratio (Quarterly)2.62x

Enterprise Value$712.29M

Asset Turnover (TTM)0.33x

Book Value / Share Growth (5Y)-49.48%

Revenue / Employee (Annual)$180,700

Pretax Margin (Annual)-397.83%

Cash / Share (Annual)$0.68

3-Month Return Std Dev64.95%

Gross Margin (5Y Avg)-120.50%

Net Income / Employee (TTM)$-1,856,800

ROE (Last FY)-253.96%

Net Interest Coverage (Annual)-95.08x

EPS Basic Excl Extra (Annual)$-1.25

P/FCF (TTM)119.91x

Receivables Turnover (TTM)20.24x

Total Debt / Equity (Quarterly)1.40x

EPS Incl Extra (TTM)$-1.11

Receivables Turnover (Annual)20.65x

ROI (TTM)-132.45%

P/S Ratio (TTM)40.71x

Pretax Margin (5Y Avg)-159.73%

Revenue / Share (Annual)$506.00

Tangible BV / Share (Annual)$0.39

Price vs S&P 500 (52W)153.61%

Year-to-Date Return59.76%

5-Day Price Return5.59%

EPS Normalized (Annual)$-1.25

ROA (5Y Avg)-119.77%

Net Profit Margin (Annual)-397.83%

Month-to-Date Return23.68%

EBITD / Share (Annual)$-1.26

Operating Margin (Annual)-418.77%

LT Debt / Equity (Annual)0.52x

ROI (5Y Avg)-114.02%

LT Debt / Equity (Quarterly)0.87x

EPS Basic Excl Extra (TTM)$-1.11

P/TBV (Quarterly)15.68x

P/B Ratio (Annual)12.30x

Pretax Margin (TTM)-94.67%

Book Value / Share (Annual)$0.40

Price vs S&P 500 (13W)69.81%

Beta2.36x

P/FCF (Annual)20.81x

Revenue / Share (TTM)$212.00

ROE (TTM)-193.49%

52-Week Low$2.62

vGradeF

gGradeF

mGradeA

vgmGradeD

ACHV Earnings Surprise History

Q2 25-0.37est. -0.35

Q3 25-0.28est. -0.26

Q4 25-0.28est. -0.28

Q1 26-0.19est. -0.30

Q2 26-0.80est. -0.16

ACHV Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.07

4.13

Industry Peers — In Vitro Diagnostics(18)

Symbol	Value Score	Growth Score	Momentum Score	Price
ACHVAchieve Life Sciences, Inc.	F	F	A	$8.17
IDXXIdexx Laboratories Inc	D	B	C	$550.01
LNTHLantheus Holdings, Inc	C	B	B	$100.87
CLDXCelldex Therapeutics, Inc	F	F	B	$41.22
NEOGNeogen Corp	C	C	B	$11.64
NTLAIntellia Therapeutics, Inc	D	D	C	$13.51
QDELQuidelOrtho Corporation Common Stock	C	C	C	$15.05
TKNOAlpha Teknova, Inc. Common Stock	D	C	A	$7.46
NNNNAnbio Biotechnology Class A Ordinary Shares	F	B	F	$7.83
MYGNMyriad Genetics Inc	B	C	D	$3.19
IMDXInsight Molecular Diagnostics Inc. Common Stock	F	D	C	$4.44
ICCCImmucell Corp	C	B	B	$9.84
QCLSQ/C Technologies, Inc. Common Stock	C	—	F	$2.44
TRIBTrinity Biotech plc	B	D	F	$9.71
CDIOCardio Diagnostics Holdings Inc. Common stock	—	C	B	$1.91
BMRABIOMERICA INC	B	D	D	$1.77
VNRXVolitionRx Limited	B	A	F	$0.38
VRAXVirax Biolabs Group Limited Ordinary Shares	—	B	D	$2.91
CDIOWCardio Diagnostics Holdings Inc. Warrant	—	—	C	$0.01

About Achieve Life Sciences, Inc.

Achieve Life Sciences is a specialty pharmaceutical company developing and commercializing cytisinicline, an established smoking cessation treatment approved in Central and Eastern Europe. The company aims to expand cytisinicline's availability as a treatment for nicotine addiction and address the global smoking health epidemic.